#SER↓

SER/ 01/28/2026 · 5:25 PM

FDA Clears Serina's Advanced Parkinson's Disease Drug for Clinical Trial

Serina Therapeutics receives FDA IND clearance for SER-252, advancing toward Phase 1b clinical study for advanced Parkinson's disease treatment using POZ platform technology.

SER/ 08/26/2025 · 6:06 AM

Serina Therapeutics' SER-252 Gains Momentum for Advanced Parkinson's Treatment

Serina Therapeutics’ SER-252 for advanced Parkinson's gains FDA support for a registrational study via the 505(b)(2) NDA pathway. The POZ Platform enables continuous dopaminergic stimulation, aiming to improve motor fluctuations.